DOX-TTPNs also successfully sensitized TRAIL-resistant xenograft tumors of the colorectal cancer cell line HT29 to the apoptotic effects of TRAIL in vivo, even at a very low dose of the incorporated DOX, underscoring the potential of this platform as an antitumor agent [107]. Here, TNFSF10 is linked to colorectal cancer.